About
Deep Intelligent Pharma (DIP), founded in 2017 in Beijing, China, is an AI-driven drug discovery and clinical development platform with a multi-agent system.
Technology & BusinessWhat · How · Which stage
Research Areas生命科学医药HighEvidence
2026-09-09技术能力专项复核：依据公司简介、官网公开材料及统一任务映射规则，将泛化“AI药物研发”细分为知识推理与科研Agent、临床研究与开发、预测与筛选、仿真与科学计算；未把公司愿景或管线阶段直接视为技术能力。
Source：Official site · Updated 2026-09-09 · View source
Capabilities临床研发仿真与科学计算科研 Agent预测筛选HighEvidence
2026-09-09技术能力专项复核：依据公司简介、官网公开材料及统一任务映射规则，将泛化“AI药物研发”细分为知识推理与科研Agent、临床研究与开发、预测与筛选、仿真与科学计算；未把公司愿景或管线阶段直接视为技术能力。
Source：Official site · Updated 2026-09-09 · View source
Subjects药物与候选疗法HighEvidence
IT桔子公司画像明确词：新药、药物；映射为：药物与候选疗法
Updated 2026-09-10
R&D Stages临床开发与注册分子设计与先导优化机制与靶点发现靶点验证与苗头发现HighEvidence
IT桔子公司画像明确词：研发；映射为：药物研发（具体阶段待核验）；2026-09-09药物研发环节标准化：原“科学发现与靶点识别；设计、生成与虚拟筛选；仿真与计算验证；临床开发与转化”映射为“疾病机制研究与靶点发现；靶点验证与苗头发现；分子设计与先导优化；临床开发与注册转化”
Updated 2026-09-10
Business Model自研产品或研发管线软件/SaaS/科研平台HighEvidence
2026-09-09技术能力专项复核：依据公司简介、官网公开材料及统一任务映射规则，将泛化“AI药物研发”细分为知识推理与科研Agent、临床研究与开发、预测与筛选、仿真与科学计算；未把公司愿景或管线阶段直接视为技术能力。
Source：Official site · Updated 2026-09-09 · View source
Full tier & rationale — an SVTR Intelligence benefit
Timeline
- 2026-03FundingSeries D+$40M
- 2026-02FundingSeries D+$60M
- 2025-12FundingSeries D+$50M
Public events aggregated from this page; rating changes are member-only.
Capital graph
Founders / core team
Investors
Funding history
- 2026-03Series D+$40M
Investors · XIN DING Capital, Jinyi Capital, Kaitai Capital
- 2026-02Series D+$60M
Investors · CDH Investments, XIN DING Capital, Kaitai Capital, Trustar Capital, Jinyi Capital
- 2025-12Series D+$50M
Investors · CDH Baifu, XIN DING Capital
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Deep Pharma
AI-driven drug discovery and clinical development platform
Series D+ · $200M · 2026-03
$200M
United States
BusinessLatest roundTotal raisedDate- Topos Bio
AI-driven drug discovery targeting intrinsically disordered proteins
Seed · $107M · 2026-01
$107M - LifeMine Therapeutics
A clinical-stage precision drug discovery company based on fungal genome mining, developing novel therapies in transplantation and immunology.
Series D+ · $558M · 2026-08
$558M - Pathos AI
Uses artificial intelligence and robotic automation to accelerate the development of targeted therapies for solid tumors
Series D+ · $365M · 2025-05
$365M
China
BusinessLatest roundTotal raisedDate- Anew Labs
AI-driven drug discovery and new drug development platform
Undisclosed · $290M · 2026-09 · Valuation $1.5B
$290MValuation $1.5B - Insilico Medicine
AI drug discovery company that uses generative models for target discovery and molecular design, and has advanced multiple drug candidates into clinical trials
Series D+ · $210M · 2025-03
$210M - Syneron Bio
AI-driven synthetic peptide drug developer focused on a pipeline of next-generation synthetic peptide and protein drugs
Series B · $280M · 2026-04
$280M
Europe
BusinessLatest roundTotal raisedDate- Aqemia
Cancer drug discovery using generative AI and quantum physics
Undisclosed · $71M · 2024-12
$71M - Basecamp Research
Trains the EDEN foundation model on proprietary biodiversity genomic data and uses AI to design proteins and in vivo cell therapies
Series C · $200M · 2026-09
$200M - Isomorphic Labs
AI-driven drug design platform (IsoDDE engine): uses AlphaFold-based technology to predict protein structures and design new drug molecules; builds its own therapeutic pipeline and conducts joint R&D with large pharmaceutical companies
Series B · $2.7B · 2026-05
$2.7B
Other / unspecified
BusinessLatest roundTotal raisedDateConfirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
Dimension Capital
10 Life Sciences deals in the last 24 months · 4 at a nearby stage · 1 in North China
Request intro →Qiming Venture Partners
9 Life Sciences deals in the last 24 months · 1 at a nearby stage · 7 in North China
Request intro →B Capital
5 Life Sciences deals in the last 24 months · 2 at a nearby stage · 1 in North China
Request intro →Tencent
4 Life Sciences deals in the last 24 months · 1 at a nearby stage · 4 in North China
Request intro →Delian Capital
4 Life Sciences deals in the last 24 months · 1 at a nearby stage · 4 in North China
Request intro →Gaorong Ventures
3 Life Sciences deals in the last 24 months · 1 at a nearby stage · 2 in North China
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.